15 September 2023 - Positive opinion is based on Phase 3 studies which showed long-term response in skin clearance and itch control.

Almirall today announced that the CHMP of the EMA issued a positive opinion recommending the marketing authorisation of Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe atopic dermatitis, who are candidates for systemic therapy.

Read Almirall press release